2 results
Approved WMOPending
To evaluate the efficacy and safety of extended release (ER) Niacin/Laropiprant when added to ongoing lipid-modifying therapy in patients with primary hypercholesterolemia or mixed dyslipidemia.
Approved WMOWill not start
Primary ObjectivesPhase 1bConfirm the recommended CyPep-1 dose 20 mg every two weeks (Q2W) when administered by intratumoral (IT) injection in combination with pembrolizumab Phase 2aAssess the anti-tumor activity of CyPep-1 administered by IT…